Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Study EV-103: Update on durability results and long term outcome of enfortumab vedotin plus pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC). Friedlander, T. W., Milowsky, M. I., Bilen, M., Srinivas, S., Mckay, R. R., Flaig, T. W., Hoimes, C. J., Balar, A., Henry, E., Petrylak, D. P., Sasse, C., Kataria, R. S., Yu, Y., Carret, A., Rosenberg, J. E. LIPPINCOTT WILLIAMS & WILKINS. 2021
View details for DOI 10.1200/JCO.2021.39.15_suppl.4528
View details for Web of Science ID 000708120602276